N@N

Incyte to Host Conference Call to Discuss Its Collaboration with Lilly for the Development and Commercialization of Oral Anti-I

_{//health-fitness.news-articles.net/content/2009/ .. opment-and-commercialization-of-oral-anti-i.html}
^{Published in Health and Fitness on Monday, December 21st 2009 at 4:41 GMT by Market Wire}  

WILMINGTON, Del.--([ BUSINESS WIRE ])--Incyte Corporation (Nasdaq:INCY) announced today that it has scheduled a conference call for 8:30 a.m. ET on Monday, December 21, 2009.

• Conference Call: December 21, 2009 at 8:30 a.m. ET
• Domestic Dial In Number: 877-407-8037
• International Dial In Number: 201-689-8037
• Conference ID # 340419

If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and dial-in number for international callers is 201-612-7415. To access the replay you will need the conference account number 278 and the ID number 340419.

The conference call will also be webcast live on CCBN and can be accessed at [ www.incyte.com ] under Investor Relations, Events and Webcasts.

About Incyte

Incyte Corporation is a Wilmington, Delaware-based drug discovery and development company focused on developing proprietary small molecule drugs for oncology, inflammation and diabetes. Incyte's most advanced compound, INCB18424, is in Phase III development for myelofibrosis. For additional information on Incyte, visit the Company's web site at: [ www.incyte.com ].